InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the detailed record of transactions filed by Kaplan Gilla. Director active across 2 companies, notably Avalo Therapeutics, Inc.. In total, 6 filings have been published. Split: 0 buy · 2 sells. Total volume traded: €267k. History available since 13 June 2024. The latest transaction was disclosed on 25 March 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations
KAPLAN GILLA is a declarant linked to Tyra Biosciences, Inc. and Avalo Therapeutics, Inc., where the listed role is Director. The record shows 5 filings in total, and across the 5 sampled filings, buys are EUR 0 and sells are EUR 266683, with a date range from 2024-06-18 to 2026-03-31. The modal transaction nature is Levée d'options.